Introduction: Long-term data on outcomes of operable stage III NSCLC are scarce.
Results: With the sixth version, the 5-and 10-year survival rates were 38% and 28% for stage IIIA, respectively, and 36% and 24% for stage IIIB, respectively. Factors associated with improved 5-year overall survival were younger age, R0 resection, and pathologic complete remission (pCR) (p ¼ 0.043, p < 0.001 and p ¼ 0.009). With the eighth TNM staging version, 162 patients were moved from stage IIIA to IIIB*. The 5-and 10-year survival rates were 41% and 29% for stage IIIA*, respectively, and 35% and 27% for stage IIIB* patients, respectively. There was no difference in the bi-versus trimodal group with regard to median overall survival (28 
Conclusions:
We showed favorable 10-year survival rates of 29% and 27% in stage IIIA* and IIIB*, respectively. Younger age, R0 resection, and pathologic complete response were associated with improved long-term survival. Outcomes using the sixth versus eighth edition of the TNM classification were similar in operable stage III NSCLC.
Introduction
Five-year survival rates of patients with stage III NSCLC range from 13% to 36%. 1 Reports on long-term outcomes of patients with stage III NSCLC beyond 5 years who have received multimodal treatment including surgery are scarce. 2, 3 The Swiss Group for Clinical Cancer Research (SAKK) has been investigating the optimal management of stage III NSCLC since 1996 in a phase III (SAKK 16/00) and two phase II (SAKK 16/ 96 and SAKK 16/01) studies, building on a backbone of induction chemotherapy with cisplatin and docetaxel. [4] [5] [6] In all three trials, the 1995 mountain staging classification (i.e., the fifth TNM version) which was based on 5319 lung cancer patients only, was used for enrollment. 7 For lung cancer, there was no change from the fifth to the sixth TNM version. 8 The SAKK trials showed that surgery could be safely performed after induction chemotherapy or chemoradiotherapy in centers with adequate expertise. Treatment consisted of either neoadjuvant chemotherapy or neoadjuvant chemotherapy followed by preoperative radiotherapy plus surgery. All trials enrolled a very similar patient population and used a nearly identical treatment regimen. The SAKK 16/01 enrolled patients with T4N0-3 or T1-4N3 (excluding malignant pleural or pericardial effusion, invasion of the aorta, esophagus, myocardium, and supraclavicular nodes N3), whereas the SAKK 16/96 and 16/00 included T1-3N2M0 patients only.
Herein we report on long-term outcomes of a pooled analysis of these trials. In addition, we aimed to evaluate prognostic factors and the impact of the new eighth TNM staging system (accompanied by an asterisk [*] throughout the article) which is now based on data from 70,967 NSCLC patients and therefore predicts prognosis more accurately. [9] [10] [11] [12] [13] [14] [15] [16] The major changes in the current classification compared to the sixth version include further subdivision of the T category, same lung lobe metastases changing from T4 to T3*, and different lobe/ ipsilateral lung metastases becoming T4* instead of M1. For stage III specifically, stage IIIC* (T3/4N3, previously stage IIIB) was added and T4N0-1* was reclassified from IIIB to IIIA* and T3N2* from IIIA to IIIB*. A new staging classification does not automatically imply that treatment algorithms can be transferred. This is particularly relevant in stage III because of the potential for cure and the various treatment options including concurrent definitive chemoradiation, preoperative chemotherapy, or preoperative chemoradiation in operable stage IIIA disease, and most commonly definitive concurrent chemoradiation therapy in stage IIIB disease. [17] [18] [19] [20] [21] Similar to stage IIIA, stage IIIB represents a particularly heterogeneous group, and selected patients may still benefit from surgery following prior neoadjuvant chemotherapy or chemoradiotherapy resulting in similar outcomes as stage IIIA patients. 3, 22, 23 The implication of the eighth staging classification on optimal treatment selection and outcomes with multimodal therapy in stage III patients is unknown.
Another goal of our analysis was to study the effect of the addition of preoperative radiotherapy (RT) to the established induction chemotherapy regimen. In stage IIIA (N2), disease preoperative RT did not improve eventfree or overall survival (OS) in our randomized phase III trial. 4 Despite being the largest trial evaluating the role of preoperative RT in addition to preoperative chemotherapy, the overall number of patients who underwent surgery was relatively small (n ¼ 193) and the role of additional preoperative RT remains controversial.
In summary, we performed a pooled analysis of three clinical trials of operable stage III NSCLC to evaluate long-term outcomes including patterns of failures. We also evaluated factors associated with improved survival, the validity of the eighth version of the TNM classification, and the role of the addition of preoperative RT to preoperative chemotherapy.
Methods

Patient Population
All patients who participated in SAKK 16/96, SAKK 16/00, and SAKK 16/01 were included in this pooled analysis. These trials were designed for operable stage III (both stage IIIA[N2] and IIIB) and included 3 cycles of induction chemotherapy (cisplatin 100 mg/m 2 and docetaxel 85 mg/m 2 ) followed by surgery (bimodal therapy group) or neoadjuvant cisplatin/docetaxel chemotherapy with sequential neoadjuvant RT (22 Â 2 Gy over 3 weeks with accelerated concomitant boost RT), followed by surgery (trimodal therapy group). Results of the individual trials have been reported previously. [3] [4] [5] [6] 24 Three hundred sixty-eight patients were recruited between 1997 and 2012. Patients were identically staged with the exception of fluorodeoxyglucose positron-emission tomography-computed tomography (PET-CT) staging that was not available for patients recruited before the availability of PET-CT (i.e., in 32% of all patients).
To apply the latest eighth TNM staging version, tumor stages of patients who were initially T2 were transferred to T2*-T4* according to their baseline tumor size measurements (T2*: 3cm < size 5cm, T3*: 5cm < size 7cm, and T4*: size > 7cm). Additionally, patients who had separate tumor nodules in the same lobe (satellite lesions within the same lobe) were transferred from T4 to T3*.
To identify characteristics associated with long-term survival, we performed an additional analysis focusing on patients living more versus less than 5 years.
Statistical Analysis
Outcome analyses were conducted as intention to treat including all registered patients in their assigned treatment arm or according to the treatment they were supposed to receive per protocol. For this analysis, patients were attributed to either the bi-or the trimodal treatment group. Event-free survival (EFS) was defined as the time from randomization/registration until relapse/progression, second tumor (only for SAKK 16/ 00), or death due to any cause. Patients not experiencing an event were censored at the last available assessment before start of a subsequent treatment, if any. Patients not experiencing an event were censored at the last date they were known to be alive. Median EFS and OS were estimated using the Kaplan-Meier method. The log-rank test was used to check differences among survival curves. The Fisher's exact test or chi-square test was used to check differences among variables expressed as rates. Generally, a p < 0.05 was considered statistically significant. No adjustment for multiple testing was performed.
Events considered for EFS were locoregional recurrence, distant recurrence, second primary tumor, or death (irrespective of the cause in the absence of recurrence). Events counted for non-lung cancer mortality were death of known cause without recurrence and not considered as lung cancer death. Lung cancer mortality was computed by "subtraction" and included death with prior recurrence from whatever cause, death from lung cancer without previous recurrence, and death from unknown cause.
To evaluate factors associated with improved 5-year survival, a logistic regression model was performed including treatment (bimodal versus trimodal), age, sex, smoking status (continued versus stopped versus never smoked), histology (adenocarcinoma versus squamous versus large cell versus poorly differentiated), performance status (WHO 0 versus WHO 1/2), T-stage (T1* versus T2* versus T3* versus T4*), extent of surgery (pneumonectomy versus lesser resection), resection (R0 versus R1/R2), response to induction (pathologic complete remission [pCR] yes versus no), and intensity of chemotherapy (less than 60% of planned chemotherapy given: yes versus no). pCR was defined as ! 95% necrosis and fibrosis (i.e., <5% viable tumor cells) in the SAKK 16/96 trial and as no remaining tumor cells in the other trials.
Results
Three hundred sixty-eight patients were enrolled in the three SAKK trials. Patients and tumor characteristics are summarized in Table 1 according to the treatment received (bi-or trimodal treatment group) and in Supplemental Table 1 according to trial enrolled. All patients were followed until death. The cutoff date of this analysis is January 24, 2017. The median overall follow-up was 8 years (range, 0-16 years). At the time of this analysis, 18% remained free from recurrence. Longterm follow-up of patients using the sixth TNM staging classification showed 5-and 10-year survival rates of 38% and 28%, respectively, for stage IIIA and 36% and 24%, respectively, for stage IIIB. With the eighth TNM staging classification, 5-and 10-year survival rates were 41% and 29%, respectively, for stage IIIA*, and 35% and 27%, respectively, for stage IIIB*. The corresponding 5-and 10-year EFS rates were 23% and 18%, respectively, for stage IIIA*, and 24% and 14%, respectively, for stage IIIB*. The median OS was 34 months (95% confidence interval [CI]: 26-52 months) versus 26 months (95% CI: 18-40 months) in stage IIIA* versus stage IIIB* (p ¼ 0.14) (Fig. 1) . Only seven patients were categorized as stage IIIC* with 5-and 10-year survival rates of 41% and 29%, respectively, and 5-and 10-year EFS rates of 43% and 0%, respectively.
Overall, 73% died due to lung cancer. The most frequent location of relapse was distant failure in 53%, but first site of relapse was locoregional (i.e., primary tumor or locoregional lymph nodes) in 33%, whereas 14% had both locoregional and distant failure. Recurrences after 5 years occurred in less than 3% (n ¼ 10). Late recurrences included local relapse in five patients including isolated locoregional relapse in two patients and locoregional and distant failure in three patients and distant relapse in three patients (lung [n ¼ 2] and brain) and unknown relapse site in two patients. The rate of secondary malignancies after 5 years was 4%, varying among the trials from 3% to 9%. Sixteen patients were diagnosed with secondary malignancies including 10 NSCLC, one SCLC, two urothelial, and one each of hypopharynx, breast, and prostate cancer. Death without progression after 5 years of follow-up occurred in eight patients and included accident, cardiovascular (n ¼ 2), Alzheimer disease, acute respiratory failure (n ¼ 2), and unknown cause (n ¼ 2). Indicates the eighth edition of the TNM classification. Chemo, chemotherapy; RT, radiation therapy; min-max, minimummaximum; Adeno, adenocarcinoma; dif, differentiated.
With the eighth TNM classification, 162 patients were moved from stage IIIA to IIIB*. Survival of this subgroup did not differ from the other groups of patients and the median OS and EFS were 27 months (95% CI: 18-42 months) and 11 months (95% CI: 9-13 months) for stage IIIA patients changing to IIIB* versus 23 months (95% CI: 9-81 months) and 10 months for stage IIIB* (95% CI: 5-29 months) (Fig. 1) . Table 2 shows stage changes resulting with the new eighth TNM classification edition.
In the multivariate analysis, factors associated with improved 5-year survival outcomes included younger age, R0 resection, and pCR (Table 3) . Based on the expected toxicity of chemotherapy and decreased renal clearance of cisplatin in advanced age, the protocols had an upper age limit of 75 years. In an exploratory analysis, we separately analyzed patients who were older than 70 years (n ¼ 35, 24 males, 11 females), including 15 patients with squamous carcinoma, 13 with stage Fig. 2 ). In addition, there was a trend towards worse 5-and 10-year survival rates in elderly patients (23% versus 39%, p ¼ 0.058; and 16% versus 28%, p ¼ 0.13). Lung cancer mortality in the elderly was 48% versus 76% in younger patients (p ¼ 0.004). In addition, more elderly patients (34%) died of comorbid illnesses. Treatmentrelated death rates for patients older than 70 years versus those younger were 6% versus 2%, respectively, (p ¼ 0.2). Fewer elderly patients were treated with less than 60% of the planned chemotherapy dose (6% versus 11%, p ¼ 0.6). There was a trend towards a lower pneumonectomy rate in elderly patients (34% versus 17% in younger patients versus the elderly, p ¼ 0.06). The rate of R0 resections (78% versus 73% in younger patients versus the elderly, p ¼ 0.6) was similar. Bi-or trimodal treatment did not predict for 5-year survival. When analyzing patient's characteristics according to bi-versus tri-modal treatment groups, there were more patients with stage IIIA* (50% versus 41%) in the bimodal group; however, there were more patients with stage IIIC* (0% versus 4%.) in the trimodal group and a similar number of patients with stage IIIB* (51% versus 52%) in the bi-versus trimodal group, respectively, when using the eighth TNM classification (Table 1) . Other prognostic factors were similar between the two groups.
Overall, only 37% of the patients had adenocarcinoma and 17% did not receive surgery (63% of those due to progressive disease). With regard to treatment, pneumonectomy rates were similar (33% versus 31% in the bi-versus trimodal group, p ¼ 0.9), but a higher proportion of patients in the trimodal group received less than 60% of the planned chemotherapy (15% versus 6%, p ¼ 0.003). More than 99% of the patients received more than 90% of the planned preoperative RT dose. Postoperative thoracic RT was recommended in cases of R1 or R2 resection. Information on postoperative thoracic RT was available for the SAKK 16/00 trial (20 patients) and SAKK 16/96 (33 patients).
More patients receiving trimodal versus bimodal treatment had R0 resection (87% versus 69%, p < 0.001). pCR rates were not significantly associated with the use of preoperative RT (15% versus 16% in the biversus trimodal group, p ¼ 0.75), neither were lung cancer-related death rates (77% for the bimodal group versus 67% in the trimodal group, p ¼ 0.095), and grade 5 toxicity rates (2% in bimodal versus 4% in the trimodal group, p ¼ 0.12). Postoperative mortality for patients with pneumonectomy was 7% versus 2% in the bimodal versus trimodal groups, respectively (p ¼ 0.39). The majority of treatment-related deaths were attributed to surgery, mainly thromboembolic events, bleeding, and acute respiratory distress syndrome. Median OS and EFS were not significantly different between the bi-and trimodal groups ( Fig. 1 ). Importantly local recurrence rates were also not different between the two treatment groups (48% versus 44%, p ¼ 0.61). We found no influence of the sixth or eighth TNM classification on survival outcomes with regard to bi-or trimodal treatment.
Discussion
The SAKK trials offer a unique opportunity to investigate long-term outcomes of patients with locally advanced stage IIIA and stage IIIB cancer treated with preoperative chemotherapy (±RT) followed by surgery. All patients were carefully staged and had histologically proven stage IIIA/N2 or IIIB (T4 or N3) disease. Furthermore, patients received the same chemotherapy or chemo-and radiotherapy regimen. The 5-and 10-year survival rates of almost 40% and 30% show that an important proportion of patients can be cured with adequate treatment. Our results compare favorably with other trials and are particularly favorable for very advanced selected stage IIIB patients, indicating that, if properly selected, multimodal treatment including surgery leads to similar outcomes in stage IIIA and IIIB patients. 3, 22 Relapses included distant metastases in 53% of the patients with an almost equal rate of local failures (46%), indicating that both improved systemic therapy as well as local treatment approaches will be required to further improve outcomes. Immunotherapy is being explored in various trials, including our ongoing SAKK 16/14 trial (SNCTP000001480) to reduce systemic relapse rates or in combination with RT (NCT02434081) to decrease local recurrences. Further strategies to improve local control such as better target volume definition, improved conformality of RT, image-guided RT delivery, and motion management techniques are currently also pursued in clinical trials. Of all patients with a follow-up of more than 5 years (n ¼ 70), 10 patients (14%) experienced a recurrence, eight (11%) died without progression, and six (9%) had a second carcinoma, underpinning the importance of follow-up beyond 5 years.
We identified younger age, R0 resection, and pCR to be significantly associated with improved 5-year survival rates. R0 resection and pCR rates have previously been reported to be prognostic factors. 24, 25 Better outcomes in younger patients who had a median OS of 32 months compared to 22 months of patients who were 70 years or older (p ¼ 0.04) resulted from more frequent deaths due to comorbidities in the elderly group. Although we observed a trend toward higher grade 5 treatmentrelated toxicity in patients 70 years of age or older (5.7% versus 2.4%, p ¼ 0.25), this difference was not statistically significant. Increased toxicity rates in elderly patients receiving platinum-based chemotherapy have been reported. [26] [27] [28] [29] Thus, multimodal treatment including surgery can be cautiously offered to selected elderly patients as well.
The 5-and 10-year survival rates were similar when the new eighth classification system was applied with 41% and 29% versus 35% and 27% versus 43% and 29% in stages IIIA*, IIIB*, and IIIC*, respectively. Remarkably, outcomes of patients who moved from stage IIIA to IIIB* with the eighth classification were similar. This is important because 49% of our stage IIIA cohort was upstaged to stage IIIB*. Thus, the new staging system can be used for treatment decisions, and a shift from stage IIIA to IIIB* does not automatically preclude aggressive surgical treatment. In fact, in the context of operable stage III NSCLC, with the exclusion of patients with T4 due to pulmonary nodules in different lung lobes who were not studied in our analysis, the new staging system may not be able to identify prognostic differences between stage IIIA* and stage IIIB*. The rather favorable 10-year survival rates of patients with stage IIIC* must be interpreted with caution due to low patient numbers (n ¼ 7). Furthermore, no conclusion can be drawn for T4* tumors due to metastases in different lung lobes as these patients were excluded in the analyzed trials.
Given the similarity of the patient population and the homogenous treatment in the trials, we have performed a pooled analysis to evaluate outcomes of patients treated with preoperative RT versus those who received neoadjuvant chemotherapy alone. Although R0 resection rate (69% versus 87%, p < 0.001) was higher in the trimodal group, neither local recurrence nor pCR rates were higher in the trimodal group. Likewise, we found no benefit in EFS and OS of trimodal treatment strategy by adding sequentially delivered RT to induction chemotherapy before surgery. These findings correspond to a previous analysis of a large U.S. data base. 30 It is entirely possible that preoperative RT does not have an impact on survival; however, two other potential explanations have to be considered. First, small differences in patient characteristics, such as a slightly higher proportion of patients with more advanced tumor stage in the trimodal group, may have influenced our results. Second, for unknown reasons, more patients in the trimodal group received a suboptimal cisplatin dose of less than 60% of planned dose.
Our study has several strengths and limitations. This is a pooled analysis using individual patient data in the largest homogenous stage III trial population treated with one treatment regimen and at the same cancer centers over 2 decades to date. Given the excellent outcomes in a multicentric setting within Switzerland and surrounding countries, preoperative chemotherapy with cisplatin and docetaxel appears to be a valuable treatment option in patients fulfilling the required inclusion criteria (i.e., performance score 0-1, patients younger than 75 years), even outside of a clinical trial setting, provided a center has sufficient experience and appropriately trained surgeons. Also, the current study included the application of sequential preoperative RT rather than concurrent chemoradiotherapy, which is associated with inferior outcomes in inoperable stage III patients, although it is unclear whether this also holds true for the preoperative setting. 31 Our sequential hyperfractionated administration of preoperative RT was not associated with increased mortality rates, whereas previous trials resulted in increased toxicity compared to concurrent chemo-RT alone. 28 The sequential approach also allowed us to give high doses of chemotherapy (cisplatin 100 mg/m 2 and docetaxel 85 mg/m 2 ), which are not feasible with concurrent chemo-RT, and which requires the prophylactic use of granulocytecolony stimulating factors. Because PET-CT staging became available between 1997 and 2012, 32% of the patients had no initial PET-CT. However, when performing an exploratory analysis comparing EFS, OS, and long-term survival of more than 5 years for patients who received PET CT staging versus none, outcomes were identical (data not shown). Furthermore, the results of the post hoc subgroup analysis of the elderly patients should be considered purely exploratory and preliminary given the limited number of elderly patients included in the analysis (the upper age limit of patients in the trials was 75 years old). Future planned 10-year long-term analyses, including the trials SAKK 16/08 (NCT01059188) and SAKK 16/ 14 (SNCTP000001480), would be of interest in this regard.
In conclusion, this is the largest analysis of operable and identically staged and treated stage III patients. Ten-year survival rates of almost 30% are among the best reported in the literature to date, supporting the use of high doses of neoadjuvant cisplatin and docetaxel followed by surgery in this population. Most patients have distant failures indicating the need to improve systemic treatment options. Younger age, R0 resection, and pCR were associated with improved 5-year survival. With the eighth TNM classification, almost half of the patients moved from stage IIIA to IIIB*. After reclassification, multimodal treatment of stage IIIA* and B* patients including surgery lead to similar outcomes, and the eighth TNM classification edition can be used (at least in stage IIIA*/B*) for treatment decisions, although no statement for IIIC* can be made because of low patient numbers and for patients with T4* due to metastases in different lobes as they were excluded in the trials. Survival did not improve with the addition of preoperative sequential RT to neoadjuvant chemotherapy, although small imbalances in prognostic factors favoring the bimodal group may have mitigated a potential beneficial effect of preoperative RT.
